Oral preexposure prophylaxis to prevent HIV infection: Clinical and public health implications

被引：1

作者：

Baker, Jonathan ^{[1
]}

O'Hara, Kevin Michael ^{[2
]}

机构：

[1] Univ Pittsburgh Pa Med Ctr, Div Infect Dis, Pittsburgh, PA 15261 USA

[2] Yale Univ, PA Program, New Haven, CT USA

来源：

JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS | 2014年 / 27卷 / 12期

关键词：

HIV; preexposure prophylaxis (PrEP); tenofovir; emtricitabine (FTC); antiretroviral; harm reduction; TENOFOVIR DISOPROXIL FUMARATE; IMMUNODEFICIENCY-VIRUS; UNITED-STATES; ANTIRETROVIRAL PROPHYLAXIS; COST-EFFECTIVENESS; MEN; RISK; SEX; TRANSMISSION; EMTRICITABINE;

D O I：

10.1097/01.JAA.0000456567.37724.e0

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This article reviews the use of combination emtricitabine (FTC)/tenofovir as preexposure prophylaxis (PrEP) for HIV-negative patients at high risk of acquiring HIV, including heterosexual men and women, men who have sex with men, and IV drug users. When used with classic prevention strategies such as condoms, PrEP has been found effective in reducing the risk of HIV transmission.

引用

页码：10 / 17

页数：8

共 42 条

[1] Factors Influencing the Emergence and Spread of HIV Drug Resistance Arising from Rollout of Antiretroviral Pre-Exposure Prophylaxis (PrEP)
Abbas, Ume L.
Hood, Gregory
Wetzel, Arthur W.
Mellors, John W.
[J]. PLOS ONE, 2011, 6 (04):
[2] [Anonymous], 20 C RETR OPP INF AT
[3] [Anonymous], HIV US GLANC
[4] [Anonymous], PREEXP PROPH PREV HI
[5] [Anonymous], TRUV EMTR TEN DIS FU
[6] [Anonymous], 2015, C RETR OPP INF ATL M
[7] Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women
Baeten, J. M.
Donnell, D.
Ndase, P.
Mugo, N. R.
Campbell, J. D.
Wangisi, J.
Tappero, J. W.
Bukusi, E. A.
Cohen, C. R.
Katabira, E.
Ronald, A.
Tumwesigye, E.
Were, E.
Fife, K. H.
Kiarie, J.
Farquhar, C.
John-Stewart, G.
Kakia, A.
Odoyo, J.
Mucunguzi, A.
Nakku-Joloba, E.
Twesigye, R.
Ngure, K.
Apaka, C.
Tamooh, H.
Gabona, F.
Mujugira, A.
Panteleeff, D.
Thomas, K. K.
Kidoguchi, L.
Krows, M.
Revall, J.
Morrison, S.
Haugen, H.
Emmanuel-Ogier, M.
Ondrejcek, L.
Coombs, R. W.
Frenkel, L.
Hendrix, C.
Bumpus, N. N.
Bangsberg, D.
Haberer, J. E.
Stevens, W. S.
Lingappa, J. R.
Celum, C.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (05) : 399 - 410
[8] Stay current with options for HIV prevention
Baker, Jonathan
[J]. JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2013, 26 (12): : 14 - 20
[9] Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine
Bessesen, M
Ives, D
Condreay, L
Lawrence, S
Sherman, KE
[J]. CLINICAL INFECTIOUS DISEASES, 1999, 28 (05) : 1032 - 1035
[10] What does the value of modern medicine say about the $50,000 per Quality-Adjusted Life-Year decision rule?
Braithwaite, R. Scott
Meltzer, David O.
King, Joseph T., Jr.
Leslie, Douglas
Roberts, Mark S.
[J]. MEDICAL CARE, 2008, 46 (04) : 349 - 356

← 1 2 3 4 5 →